IMMX Archives - Page 3 of 6

2 minute read

Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting With FDA On NXC-201 U.S. Clinical Trial

June 26, 9:49 AM

Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. ("Nexcella", "Company", "We" or "Us"), a biopharmaceutical company pioneering cell therapies targeting oncology and other

IMMX

3 minute read

Immix Biopharma Subsidiary Nexcella Announces Commencement Of NXC-201 Engineering Batches At Its U.S. CAR-T Manufacturing Site

By Happy Mohamed

May 26, 9:54 AM

U.S. engineering batches support planned expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the United States Engineering batches are the first step in transferring the Company's

IMMX

1 minute read

Movers

12 Health Care Stocks Moving In Friday’s Pre-Market Session

By Benzinga Insights

May 26, 9:06 AM

Gainers Elevation Oncology (NASDAQ:ELEV) stock increased by 65.1% to $4.97 during Friday’s pre-market session. The market value of…

EFTR

4 minute read

Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

May 22, 1:20 PM

Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.

ABSI

1 minute read

Immix Biopharma’s Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis

By Vandana Singh

May 22, 11:48 AM

Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 for relapsed or refractory multiple myel

BGNE

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

May 22, 9:06 AM

Gainers Avrobio (NASDAQ:AVRO) stock increased by 81.9% to $1.41 during Monday’s pre-market session. The company’s market cap stands…

AVRO

2 minute read

Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

May 22, 8:06 AM

Gainers SeqLL Inc. (NASDAQ: SQL) shares surged 61.1% to $0.54 in pre-market trading after dropping 14% on Friday. SeqLL recently posted a wider first-quarter loss.

BIOC

3 minute read

Immix Biopharma Announces NXC-201 Clinical Results At ASGCT: 100% Overall Response Rate In DARZALEX-Relapsed/Refractory AL Amyloidosis With Zero ICANs In Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

By Benzinga Newsdesk

May 21, 5:24 PM

8 AL Amyloidosis patients relapsed/refractory to DARZALEX®-based regimens were treated with CAR-T NXC-201100% (8/8) overall response rate and 63% (5/8) complete response (MRD 10-5) was demonstrated by NXC-201 with

IMMX

3 minute read

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted For Oral Presentation At The 26th Annual Meeting Of The American Society Of Gene And Cell Therapy

By Happy Mohamed

May 4, 12:31 PM

Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us") today announced that updated NXC-201 clinical data has been selected for presentation at the upcoming 26th

IMMX

1 minute read

What’s Going On With Immix Biopharma Stock Today

By Vandana Singh

May 3, 2:42 PM

Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'

BGNE

Feed Symbols: IMMX